OverviewIn this expert case presentation, Dr. Suresh Babu discusses the management of a rare case of Stage IV non-small cell lung cancer (NSCLC) in a young postpartum patient harboring concurrent uncommon EGFR mutations (G719X and S768I), an EML4-ALK rearrangement, and a TP53 mutation. Comprehensive molecular profiling using PCR, FISH, next-generation sequencing (NGS), and liquid biopsy enabled accurate characterisation of this complex dual-driver tumour and informed treatment selection. Given the absence of established treatment sequencing strategies for concurrent EGFR- and ALK-positive NSCLC, first-line brigatinib was selected. Key takeaway: Comprehensive molecular profiling is essential in rare dual-driver NSCLC, and individualized treatment decisions can help optimize outcomes in complex molecular scenarios. The authors and publishers are not liable for any damages arising from the use or misuse of this information.